Royalty Pharma (RPRX) Cash from Operations Growth (3y) (2022 - 2026)
Royalty Pharma (RPRX) Cash from Operations Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 34.32% |
| 10 | Royalty Pharma | 25.78 Bn | 25.18 Bn | - | -11.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.43% |
| Dec 31, 2025 | 13.22% |
| Sep 30, 2025 | 9.25% |
| Jun 30, 2025 | -14.13% |
| Mar 31, 2025 | 9.00% |
| Dec 31, 2024 | 14.86% |
| Sep 30, 2024 | 14.42% |
| Jun 30, 2024 | 7.37% |
| Mar 31, 2024 | 8.10% |
| Dec 31, 2023 | 10.95% |
| Sep 30, 2023 | 4.07% |
| Jun 30, 2023 | 7.52% |
| Mar 31, 2023 | 29.95% |
| Dec 31, 2022 | 6.01% |
| Sep 30, 2022 | 8.74% |